Key Features

Instant results using a color-coded system
Eliminate ineligible pathways in seconds
Backed by interpretable automated reports
Match patients with suitable devices and related trials
Focus on viable treatment paths that matter to the patient

REC Rapid Eligibility Check

One click Pre-Screening: AI driven assessments of patient eligibility

How it works

Start your free trial

Mitral Valve - TMVR REC Pre-Screening was presented at New York Valves 2024

Streamlining Transcatheter Mitral Valve Replacement Screening: A Comparative Analysis of Fully Automated AI-Based CT Analysis versus Manual Core-Lab Approach

Presented by Dr. Jonathan Curio

PD Dr. Matti Adam, PD Dr. Mani Arsalan, Dr. Martin Beyer, Prof. Dr. Lenard Conradi, Dr. Jonathan Curio, Prof. Dr. David Leistner, PD Dr. Andreas Schäfer and Prof. Dr. Thomas Walther
Read the slides here.

Dr. Matti Adam

Interventional cardiologist | University Hospital, Cologne

"The ability to quickly and accurately assess patient eligibility for mitral valve procedures has significantly improved the workflow in our research project.

I'm convinced that this is a game changer that will allow us to focus on the viable treatment pathways and improve the care of our patients.”

Julian Praceus

CEO and Co-Founder LARALAB GmbH

"REC is set to save substantial time for heart teams by swiftly indicating viable pathways and eliminating ineligible options for patients.

The patient screening for new Mitral and Tricuspid interventions is extensive - it works in a trial setting but not yet to serve the large number of patients in need. We designed REC to enable this transition.”